Trials / Completed
CompletedNCT02483234
Psoriasis-Arthritis & Bone Program
Evaluation of Inflammatory and Structural Joint Damage in Patients With Psoriasis and Psoriatic Arthritis Treated With Secukinumab: A Phase 2, Single Arm, Single Centre Mode of Action Study (Psoriasis-Arthritis & Bone Program, PSARTROS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Erlangen-Nürnberg Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Purpose and rationale: To define the role of IL-17 as a mediator of structural bone lesions in psoriasis patients and patients with PsA. Primary Objective is the improvement of the PsAMRIS synovitis score baseline vs. week 24. Drug tested is Secukinumab 300 mg administered weekly for 4 weeks, then 4 weekly s.c. with a duration total of 24 weeks. Indication for this study is Psoriasis (Pso) and psoriatic arthritis (PsA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | secukinumab |
Timeline
- Start date
- 2015-05-31
- Primary completion
- 2018-06-30
- Completion
- 2018-09-30
- First posted
- 2015-06-26
- Last updated
- 2019-09-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02483234. Inclusion in this directory is not an endorsement.